Key Highlights
- Net loss per share was USD 0.25 against an estimate of a USD 0.347 loss.
- Net loss was USD 7.00 million, compared with USD 6.01 million.
- Total operating expenses were USD 8.84 million, compared with USD 7.34 million.
- Cash and cash equivalents were USD 41.97 million at September 30, 2026.
Unicycive Therapeutics (NASDAQ:UNCY) reported a net loss of USD 7.00 million for the third quarter of 2026, compared with a net loss of USD 6.01 million in the third quarter of 2025. The net loss per share was USD 0.25, compared with USD 0.33, against an estimate of a USD 0.347 loss.
The Quarterly Report did not state a Revenue figure for the period.
Operating Expenses
Research and development expense was USD 2.25 million, compared with USD 2.96 million. General and administrative expense was USD 6.60 million, compared with USD 4.38 million. Total operating expenses, which equal the loss from operations, were USD 8.84 million, compared with USD 7.34 million.
Interest income was USD 0.50 million, compared with USD 0.28 million, and the change in Fair Value of the Warrant Liability was USD 1.34 million, compared with USD 1.07 million.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 21.54 million, compared with USD 11.89 million, and the net loss per share was USD 0.82, compared with USD 0.85. Research and Development expense was USD 6.64 million, compared with USD 6.87 million, and general and administrative expense was USD 20.78 million, compared with USD 15.42 million. Total operating expenses were USD 27.42 million, compared with USD 22.29 million. The change in fair value of the warrant liability was USD 4.54 million, compared with USD 9.79 million.
Balance Sheet
Cash and cash equivalents were USD 41.97 million at September 30, 2026, compared with USD 29.20 million at December 31, 2025. Marketable securities were USD 17.01 million, compared with USD 12.07 million. Total Assets were USD 69.93 million, compared with USD 49.14 million, and total stockholders' Equity was USD 52.62 million, compared with USD 30.20 million.
The company states that its accumulated Deficit was USD 127.8 million at December 31, 2025 and USD 149.4 million at September 30, 2026, that it anticipates continuing to incur losses, and that it is required to raise additional Capital to complete its planned clinical trials. The filing reports 29,184,509 shares of common stock outstanding as of November 16, 2026, and weighted-average shares outstanding of 28,270,842 for the quarter, compared with 18,065,389.
The company describes UNI 494, a pro-drug of nicorandil under development as a treatment for acute kidney injury. The filing states that if the FDA accepts a new drug application for oxylanthanum carbonate, the company is required to pay USD 0.2 million to Altair Nanomaterials, and that if FDA approval is received it is required to pay USD 4.5 million to Altair. It also describes a payment of USD 1.65 million to Sphaera if the FDA accepts a new drug application for the product.
Unicycive Therapeutics Q3 2026 Earnings: Key Takeaways
Unicycive Therapeutics reported a third quarter 2026 net loss of USD 7.00 million and a loss per share of USD 0.25. Cash and cash equivalents were USD 41.97 million at September 30, 2026.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...